CONDENSED CONSOLIDATED STATEMENTS OF INCOME (OPERATIONS) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue
Total operating revenue	$ 60,921	$ 49,844	$ 116,082	$ 98,424
Operating expenses
Selling, general and administrative expense	28,348	11,212	58,154	22,390
Depreciation and amortization	1,098	794	2,085	1,571
Total operating expenses	79,225	50,960	152,857	101,293
Loss from operations	(18,304)	(1,116)	(36,775)	(2,869)
Other non-operating expense (income)
Interest expense	61	81	135	182
Change in fair value of derivative warrant liabilities	(2,065)	0	(604)	0
Change in fair value of earnout liabilities	(10,800)	0	(50,240)	0
Gain on debt extinguishment	0	(5,186)	(183)	(5,186)
Other, net	(15)	4	136	(1,072)
Total other non-operating income	(12,819)	(5,101)	(50,756)	(6,076)
Income before provision for income (loss) taxes	(5,485)	3,985	13,981	3,207
Income tax benefit (expense)	32	(780)	(148)	(998)
Net income (loss)	$ (5,453)	$ 3,205	$ 13,833	$ 2,209
Net income (loss) per share attributable to common stockholders:
Basic (in usd per share)	$ (0.06)	$ 0.05	$ 0.15	$ 0.03
Diluted (in usd per share)	$ (0.06)	$ 0.05	$ 0.15	$ 0.03
Weighted-average number of shares outstanding:
Basic (in shares)	72,996,836	66,021,829	73,123,895	64,446,377
Diluted (in shares)	72,996,836	66,021,829	76,106,201	64,446,377
Patient services
Revenue
Total operating revenue	$ 39,109	$ 29,786	$ 74,166	$ 59,408
Operating expenses
Direct costs	32,875	23,574	60,253	46,660
Dispensary
Revenue
Total operating revenue	20,218	17,782	38,897	35,400
Operating expenses
Direct costs	16,754	15,237	32,078	30,360
Clinical trials & other
Revenue
Total operating revenue	1,594	2,276	3,019	3,616
Operating expenses
Direct costs	$ 150	$ 143	$ 287	$ 312